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Abstract  
Type 2 diabetes mellitus (T2DM) is an endocrine disorder encompassing multifactorial mechanisms, and chronic 
hepatitis C virus infection (CHC) is a multifaceted disorder, associated with extrahepatic manifestations, including 
endocrinological disorders. CHC and T2DM are associated, but the subject remains controversial.  
We performed a systematic review and meta-analysis evaluating such association, searching on PubMed until February 
29, 2016. 
Inclusion criteria were: 1) presence of at least one internal control group age- and gender-matched (non-hepatopathic 
controls; and/or hepatopathic, not HCV-positive, controls); 2) sufficient data to calculate odds ratio and relative risk. 
Exclusion criteria were: 1) literature reviews on the topic; 2) publications regarding special populations [human 
immunodeficiency virus and human T-lymphotropic virus-1 coinfections, hepatocellular carcinoma (HCC), post-
transplantation DM, gender selection]; 3) no clear differentiation among HCV patients with CHC, cirrhosis or HCC.  
Data from each study were independently extracted by two reviewers and cross-checked by AA. 
Our systematic review returned 544 records, and 33 were included in our meta-analysis.  
HCV infection is associated with an increased risk of T2DM independently from the severity of the associated liver 
disease, in CHC and cirrhotic HCV patients. As expected T2DM risk is higher in cirrhotic HCV patients, than CHC, 
and the prevalence of HCV infection in T2DM patients is higher than in non-diabetic controls. Regarding HBV 
infection prevalence, no difference exists in diabetic and non-diabetic subjects.  
An unequivocal CHC and T2DM association was shown. A proactive, integrated approach to HCV and T2DM 
therapies should maximize benefits of both diseases treatment. 
 
 
Keywords: Hepatitis C virus; hepatitis C extra-hepatic manifestations; hepatitis B virus; type 2 diabetes mellitus; meta-
analysis. 
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hepatitis C virus - HIV, human immunodeficiency virus - HTLV, human T-lymphotropic virus - IR, insulin resistance - 
NIDDM, non-insulin dependent diabetes - OR, odds ratio - PTDM, post transplantation diabetes mellitus - RR, relative 
risk - SVR, sustained virological response - T2DM, type 2 diabetes mellitus.  
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Introduction  
Hepatitis C virus (HCV) infection and diabetes mellitus (DM) are two major public health problems worldwide that 
cause devastating health and financial burden [1,2]. 
There is an ever-increasing prevalence of type 2 DM (T2DM), that currently affects over 370 million people worldwide 
[3]. Normal regulation of glucose metabolism is determined by a feedback loop involving the islet β-cell and insulin-
sensitive tissues in which tissue sensitivity to insulin determines the magnitude of the β-cell response [4]. When insulin 
resistance (IR) is present, the β-cell maintains normal glucose tolerance by increasing insulin output. It is only when the 
β-cell is incapable of releasing sufficient insulin in the presence of IR that glucose levels rise. While β-cell dysfunction 
has a clear genetic component, environmental changes play a vital role [5]. 
Moreover, there are several causes and associations known to be involved in the development of DM. 
Seconday forms of DM are frequently disregarded [6]. Growth hormone (GH) deficiency, polycistic ovarian 
syndrome, testosterone deficiency, and others can lead to impaired glucose tolerance and DM [6]. 
Also “Non-Alcoholic Fatty Liver Disease” (NAFLD) is associated with insulin resistance, and/or diabetes [7]. 
NAFLD can present in a simple form characterized by lipid accumulation in the liver, however in about 20% of 
patients NAFLD progresses to “Non-Alcoholic Steatohepatitis” (NASH), characterized by hepatocellular injury, 
hepatic inflammatory infiltrates and fibrosis [7]. Both NAFLD, and NASH, are strongly associated with 
abnormal glucose tolerance, dyslipidemia, obesity, and diabetes [8].  
Recently many studies have suggested that chronic hepatitis C virus infection (CHC) is associated with T2DM [9]. 
CHC patients develop at least one extrahepatic manifestation, that consists of autoimmune disorders, as mixed 
cryoglobulinemia (MC), Sjogren’s syndrome, and endocrinological diseases such as autoimmune thyroid 
disorders (AITD) or type 2 diabetes [10]. In genetically predisposed subjects in particular conditions, viruses and 
molecular mimicry between microbial and human antigens can turn a defensive immune response into 
autoimmunity [11]. Molecular mimicry has been studied much less in endocrinology, as the majority of papers 
concerns diabetes, and to a lesser extent, thyroid, pancreas and infertility [11]. 
However the association between CHC and T2DM is not consistent across all studies, and the subject remains 
controversial [12-21]. Furthermore this association could be due to different pathogenetic mechanisms, related to the 
changes that HCV induces in the liver, or to systemic and extra-hepatic effects of the infection itself [22]. 
Here, we sistematically reviewed literature records, identified through PubMed database searching, on the increasing 
evidence of a link between HCV infection and the development of T2DM to understand whether epidemiological 
studies could confirm such a relationship, and then we performed a meta-analysis.  
 
Methods 
Systematic Review 
The methods and findings of the present review have been reported based on the preferred reporting items for 
systematic reviews and meta-analysis checklist (PRISMA). Figure 1 provides a flow chart of the present review. 
We searched the literature on PubMed library combining the terms “diabetes”, “diabetes mellitus”, “type 2 diabetes 
mellitus”, “type 2 DM”, “T2DM”, “non-insulin dependent diabetes”, or “NIDDM” and “hepatitis”, “hepatitis C”, 
“hepatitis C virus”, “ HCV”, “HVC”, or “chronic hepatitis” and “risk”, “risk factor”, “case-control”, “cohort”, “clinical 
trial”, “crosssectional”, “epidemiology”, “observational”, “meta-analysis”, “systematic review”, or “review”. 
We used no language or time restrictions. Search was concluded on February 29, 2016. 
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Two investigators independently reviewed the retrieved articles in two stages; first assessing relevance from the title 
and abstract and if relevance was still unclear, the full text was read. Any disagreement about inclusion was referred to 
a third reviewer and resolved by discussion.  
Only epidemiological studies evaluating the possible association of HCV with T2DM (with respect to an internal 
control group), with a cross sectional, or longitudinal design, were selected. 
We considered as inclusion criteria: 1) the presence of at least one internal control group matched by age and gender 
[non-hepatopathic controls; and/or hepatopathic, not HCV-positive, controls]; 2) provision of sufficient data to calculate 
odds ratio [OR] and relative risk [RR]. Exclusion criteria were: 1) literature reviews on the topic; 2) publications 
regarding special populations [see human immunodeficiency virus (HIV) and human T-lymphotropic virus (HTLV)-1 
coinfections, hepatocellular carcinoma (HCC), post transplantation diabetes mellitus (PTDM), gender selection]; 3) no 
clear differentiation among HCV patients with chronic hepatitis (CH), cirrhosis or HCC.  
 
Data collection 
Data from each study were independently extracted by two reviewers and cross-checked by AA. 
We recorded author and year of publication, samples size, hepatic definition status (healthy, CH, or cirrhosis) and 
diabetes definition status (presence or absence). 
 
Statistical analysis 
According to other similar studies [23,24] the results of the controlled studies were cumulated (see Tables), and 
analyzed performing the OR, and RR, by Java-Stat 2-way Contingency Table Analysis, STATA, and StatView.  
Relative risks with 95% confidence intervals were calculated. The heterogeneity between studies was measured using 
I^2 values, the following ranges were considered for the analysis: no heterogeneity (I^2=0–25%); moderate 
heterogeneity (I^2=25%–50%); high heterogeneity (I^2=50%–75%); maximum heterogeneity (I^2=75%–100%). 
Egger's test was performed to value publication bias. Data were elaborated using Comprehensive Meta-Analysis 
software (Version 2) and summarized in the following forest plots (see Figure 2a, 2b, 2c, 3a, 3b, 3c, 4a, 4b).  
 
Results 
Our initial search yelded 544 articles, 145 of which had relevant titles and abstracts. Multiple publications using the 
same data were deleted. After accurate assessment 71 studies met our inclusion criteria (Figure 1), of which 33 were 
included in our meta-analysis [25-57], while 38 were excluded at the stage of data extraction (Figure 1) [12-21,58-85]. 
Since cirrhosis of whatever origin is associated with T2DM, we have analyzed separately data of HCV patients affected 
by CHC (Tables 1a, b, c), from those of HCV patients with cirrhosis (Tables 2a, b, c). Furthermore, we have presented 
data about HCV prevalence in diabetic patients in Table 3a, and for comparison data about HBV prevalence in diabetic 
patients in Table 3b.  
The results of the studies that have evaluated patients with CHC (without cirrhosis) in comparison with “normal” non 
hepatopathic controls (matched by age and gender) are reported in Table 1a. A total of 1046 CHC patients and 1303 
non hepatopathic controls were analyzed, showing an increased significant risk of T2DM in CHC (Fig. 2a).  
To evaluate if the presence of hepatic disorders different from HCV infection might be related to T2DM (independently 
from the presence of HCV infection) we have evaluated patients with CHC (without cirrhosis) in comparison with 
hepatopathic (not HCV-positive) controls with HBV infection, alcohol, colestatic or cryptogenic related disorders 
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(without cirrhosis) (matched by age and gender) (Table 1b). A total of 2982 CHC patients and 1411 hepatopathic (not 
HCV-positive) controls were analyzed, showing an increased significant risk of T2DM in CHC  (Fig. 2b).  
To evaluate if the presence of hepatic disorders associated with another infection might be related to T2DM, 
independently from the presence of HCV infection, we have separately evaluated patients with CHC (without cirrhosis) 
in comparison with HBV-positive chronic hepatitis controls (HBV+CH controls) (without cirrhosis) (matched by age 
and gender) (Table 1c). A total of 2277 CHC patients and 1022 HBV+CH controls were analyzed, showing an 
increased significant risk of T2DM in HCV+CHC (Fig. 2c). 
The results of the studies that have evaluated the presence of T2DM in HCV cirrhosis, in comparison with “normal” 
non hepatopathic controls (matched by age and gender) are reported in Table 2a. A total of 207 HCV cirrhotic patients 
and 694 “normal” non hepatopathic controls were analyzed, showing an increased significant risk of T2DM in HCV 
cirrhosis (Fig. 3a). It is evident that the risk of T2DM in HCV cirrhosis is higher than in CHC patients (Fig. 3a) (OR 
6·8 versus 2·1; comparison with Table 1a). 
To evaluate if the presence of HCV infection in cirrhosis might increase the risk of T2DM, we have compared patients 
with HCV cirrhosis with non HCV-cirrhotic controls (with HBV, alcohol, colestatic or cryptogenic disorders, or 
primary biliary cirrhosis or primary sclerosing cholangitis) (matched by age and gender) (Table 2b). A total of 2401 
cirrhotic HCV patients and 1588 non HCV-cirrhotic controls were analyzed, showing an increased significant risk of 
T2DM in HCV cirrhosis (Fig. 3b).  
To evaluate if the presence of cirrhosis associated with another infection might be related to T2DM, independently from 
the presence of HCV infection, we have separately evaluated patients with HCV cirrhosis in comparison with cirrhotic 
HBV controls (matched by age and gender) (Table 2c). A total of 1868 HCV patients and 518 HBV controls were 
analyzed, showing an increased significant risk of T2DM in HCV patients (Fig. 3c).  
Data about HCV prevalence in diabetic patients versus non-diabetic controls are reported in Table 3a. A total of 7984 
T2DM patients and 34488 not diabetic controls were analyzed, showing an increased prevalence of HCV infection in 
T2DM patients (Fig. 4a).  
To evaluate if the presence of another hepatic viral infection might be related to T2DM, independently from the 
presence of HCV infection, data about the prevalence of HBV infection in diabetic patients, versus non-diabetic 
controls are reported in Table 3b, showing no significant difference (Fig. 4b).  
 
 
 
Discussion 
The results of our meta-analysis show that HCV infection is associated with an increased risk of T2DM independently 
from the severity of the associated liver disease, both in CHC patients, and in HCV cirrhotic ones. As expected, the risk 
of T2DM is higher in cirrhotic HCV patients, with respect to CHC patients. Furthermore, on the other side, the 
prevalence of HCV infection in T2DM patients is higher than in non diabetic controls; while the prevalence of HBV 
infection is not different in diabetic and non diabetic subjects. On the whole the results show an unequivocal association 
of HCV chronic infection and T2DM. 
Concerning our study, next to this strength of association, some potential limitations exist: 1) lack of generalizability of 
results (e.g. exclusion of publications regarding special population; absence of distinct observation regarding gender, 
age and ethnicity); 2) small sample size which may be unable to reflect the actual prevalence of T2DM in HCV infected 
people; 3) selection of only studies reporting on presence or absence of overt diabetes with the possibility of 
underestimating the magnitude of the relationship between HCV infection and impaired glucose metabolism; 4) 
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insufficient available informations on patients’ data for each study with consequent deficiency on further adjustments 
for important factors such as viral genotype, family history of diabetes, life style, visceral adiposity, and comorbidities. 
Indeed, analyzing literature, viral factors and host immune response and characteristics, concerning genetic background, 
life style and comorbidities, can interact in determining the increased risk for T2DM in HCV patients [86]. Most of the 
studies that have evaluated the mechanisms underlying the association between HCV and T2DM suggest that IR has a 
very important role [18]. However, other studies have suggested a dysfunction of β-cells [87], or the importance of an 
immune mediated disorder [88], in HCV T2DM patients. The knowledge of the pathogenic mechanisms involved in 
diabetes associated with HCV infection will enable us not only to further identify those patients at high risk of 
developing diabetes but also to select the best therapeutic option. 
It has become increasingly apparent that IR with or without concomitant T2DM influences longterm outcomes in CHC, 
promoting more rapid progression of liver disease [89,90], to cirrhosis [91] or HCC [92,93]. Moreover, diabetic HCV 
positive patients have an increased risk for progression respect to non diabetic subjects, and DM itself seems to have a 
selective impact on HCC development [94,95]. The connection between HCV infection and the development of DM 
increases the need for implementation of prevention measures. Prevention has to be addressed to lifestyle changes that 
can reduce the risk of HCV infection and/or developing diabetes [90], regular diabetes screening for anti-HCV positive 
persons and analysis of other risk factors that can accelerate progression of both CHC and DM, such as obesity, 
dyslipidemia, and alcohol consumption. In these high-risk patients, a comprehensive treatment including lifestyle 
modifications has to be recommended.  
Animal models also provide clues to the prevention and clinical management of diabetes in the setting of HCV infection 
[90]. Indeed, the identification of patients at risk of diabetes in CHC decelerates in liver disturbances progression [89], 
decreases incidence of HCC, and transplant-related morbidity and mortality, and improves the response to antiviral 
therapy, both increasing the likelihood of a sustained virological response (SVR), as demonstrated with interferon and 
ribavirin treatment [96] and as also conceivable, but still unclear, with new direct-acting antiviral treatment (DAA) 
[97,98], and reducing side effects of the treatment [96,99], by pretreating IR and DM [100]. 
Conversely, SVR has been demonstrated to ameliorate IR and improve β-cell function [101,102]. 
The availability of new interferon-free, well-tolerated anti-HCV treatment regimens is broadening the spectrum of 
patients available for therapy, including those in whom interferon was contraindicated, and will likely result in greater 
improvements in the extrahepatic manifestations of HCV, including diabetes. 
Actually, the effect of DAA HCV treatments on IR and long-term risk of T2DM has yet to be clearly established [103]. 
Surely many factors may interfere with the reduction of the incidence of IR and T2DM in CHC patients who obtain 
SVR after therapy (among them, HCV genotype, genetic host factors and demographic, clinical, histological and 
lifestyle characteristics of the patients). For this reason, the eradication of HCV in patients with pre-disposing factors 
for T2DM should not preclude proper counseling on diet and physical activity [104]. 
Real-world evidence studies are needed to understand the total clinical and economic effects of HCV infection (with 
both hepatic and extrahepatic related manifestations) management and treatment on patients and society [105]. 
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 Table 1a T2DM prevalence among hepatopathic patients with HCV-related chronic hepatitis (without cirrhosis) versus 
non-hepatopathic controls 
 
 
 
 
  HCV+ 
tot. 
Diabetic pts 
among 
HCV + 
n (%) 
HCV+  
without  
T2DM 
n (%)  
Non-
hepatopathic 
controls  
tot. 
Diabetic pts 
among non- 
hepatopathic 
controls 
n (%) 
Non-
hepatopathic 
controls without 
T2DM 
n (%) 
 
Odds ratio Relative risk 
Ozyilkan et al 
(1996)25 
 106 22 (20·8) 84 (79·2) 200 3 (1·5) 197 (98·5)   
Mangia et al 
(1998)26 
 102 6 (5·9) 96 (94·1) 494 48 (9·7) 446 (90·3)   
Knobler et al 
(2000)27 
 45 15 (33·3) 30 (66·7) 90 5 (5·6) 85 (94·4)   
Antonelli et al 
(2004)28 
 229 33 (14.4) 196 (85·6) 217 15  (6·9) 202 (93·1)   
Antonelli et al 
(2005)29 
 564 71 (12·6) 493 (87·4) 302 22 (7·3) 280 (92·7)   
Total  1046 147 899 1303 93 1210   
        OR 
2·12 
RR 
1·969 
95% confidence 
interval 
       1·60–2·82 
p=0·0000 
1·52–2·54  
p=0·000 
 
HCV+ = HCV-positive; pts = patients
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Table 1b T2DM prevalence among hepatopathic patients with HCV-related chronic hepatitis (without cirrhosis) versus 
hepatopathic (not HCV-positive) controls with HBV, alcohol, colestatic or cryptogenic disorders 
 
 
  HCV+ 
tot. 
Diabetic pts 
among  
HCV+ 
n (%) 
HCV+  
without  
T2DM  
n (%) 
Non HCV- 
hepatopathic 
controls  
tot. 
Diabetic pts  
among non 
HCV-
hepatopathic 
controls  
n (%) 
Non HCV- 
hepatopathic 
controls without 
T2DM 
n (%) 
Odds ratio Relative risk 
Ozyilkan et al 
(1996)25 
 106 22 (25·8)  84 (79·2) 138 9 (6·5) 
 
129 (93·5)   
Grimbert et al 
(1996)30 
 180 45 (25) 135 (75) 101 11 (11) 90 (89)   
Mangia et al 
(1998)26 
 102 6 (5·9) 96 (94·1) 36 0 (0) 36 (100)   
Caronia et al 
(1999)31 
 51 1 (2) 50 (98) 19 0 (0) 19 (100)   
Labropoulou-
Karatza et al 
(1999)32 
 39 16 (41) 23 (59) 44 5 (11·4) 39 (88·6)   
Mason et al 
(1999)33 
 212 39 (18·4) 173 (81·6) 144 14 (9·7) 130 (90·3)   
Knobler et al 
(2000)27 
 45 15 (33) 30 88 11 (12) 77   
Ryu et al 
(2001)34 
 68 16 (23·5) 52 (76·5) 157 13 (8·3) 144 (91·7)   
Arao et al 
(2003)35 
 473 72 (15·2) 401 (84·8) 108 13 (12) 95 (88)   
Lecube et al 
(2004)36 
 380 65 (17·1) 315 (82·9) 92 6 (6·5) 86 (93·5)   
Antonelli et al 
(2005)29 
 564 71 (12·6) 493 (87·4) 82 4 (4·9) 78 (95·1)   
Imazeki et al 
(2008)37 
 544 74 (13·6) 
 
470 (86·4) 286 18 (6·3) 268 (93·7)   
Rouabhia et al 
(2010)39 
 218 73 (33·5) 145 (66·5) 116 5 (4·3) 111 (95·7)   
Total   2982 515 2467 1411 109 1302   
        OR 
2·49 
RR  
2·23 
95% confidence 
interval 
       1·99–2.74 
p=0·0000 
1·83–2·74 
p=0·000 
 
HCV+ = HCV-positive; pts = patients 
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Table 1c T2DM prevalence among hepatopathic patients with HCV-related chronic hepatitis (without cirrhosis) versus 
hepatopathic HBV-positive controls 
 
  HCV+ 
tot. 
Diabetic pts 
among 
HCV + 
n (%) 
HCV+  
without  
T2DM  
n (%) 
Hepatopathic 
HBV+ 
controls 
tot. 
Diabetic pts 
among 
hepatopathic 
HBV+ controls 
n (%) 
Hepatopathic 
HBV+ controls 
without T2DM 
n (%) 
Odds ratio Relative 
risk 
Mangia et al 
(1998)26 
 102 6 (5·9) 96 (94·1) 22 0 (0) 22 (100)   
Caronia et al 
(1999)31 
 51 1 (2) 50 (98) 19 0 (0) 19 (100)   
Mason et al 
(1999)33 
 212 39 (18·4) 173 (81·6) 144 14 (9·7) 130 (90·3)   
Knobler et al 
(2000)27 
 45 15 (33·3) 30 (66·7) 88 11 (12·5) 77 (87·5)   
Ryu et al 
(2001)34 
 68 16 (23·5) 52 (76·5) 157 13 (8.2) 144 (88)   
Arao et al 
(2003)35 
 473 72 (15·2) 401 (84·8) 108 13 (12) 95 (88)   
Antonelli et al 
(2005)29 
 564 71 (12·6) 493 (87·4) 82 4 (4·9) 78 (95·1)   
Imazeki et al 
(2008)37 
 544 74 (13·6) 
 
470 (86·4) 286 18 (6·3) 268 (93·7)   
Rouabhia et al 
(2010)39 
 218 73 (33·5) 145 (66·5) 116 5 (4·3) 111 (95·7)   
Total  2277 367 1910 1022 78  944   
95% confidence 
interval 
       OR 
2·32 
RR 
2·11 
        1·78–2·69 
p=0·0000 
1·66–2·69 
p=0·000 
 
HCV+ = HCV-positive; pts = patients 
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Table 2a T2DM prevalence among hepatopathic patients with HCV-related cirrhosis versus non-hepatopathic controls 
 
 
  HCV+ 
tot. 
Diabetic pts  
among HCV + 
n (%) 
HCV+  
without  
T2DM 
n (%) 
Non-
hepatopathic 
controls 
tot. 
Diabetic pts 
among non- 
hepatopathic 
controls 
Non-
hepatopathic 
controls 
without  
T2DM 
n (%) 
Odds 
ratio 
Relative 
risk 
Ozyilkan et al 
(1996)25 
 50 19 (38) 31 (62) 200 3 (1·5) 197 (98·5)   
Mangia et al 
(1998)26 
 157 54 (34·4) 103 
(65·6) 
494 48 (9·7) 446 (90·3)   
Total  207 73 134 694 51 643   
        OR 
6·82 
RR 
4·79 
95% 
confidence 
interval 
       4·50–10·49 
p=0·000 
3·44–6·70 
p=0·000 
HCV+ = HCV-positive; pts = patients 
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Table 2b T2DM prevalence among hepatopathic patients with HCV-related cirrhosis versus non HCV-cirrhotic 
controls (with HBV, alcohol, colestatic or cryptogenic disorders, or primary biliary cirrhosis or primary sclerosing 
cholangitis) 
 
 
  HCV+ 
tot. 
Diabetic pts 
among  
HCV+ 
n (%) 
HCV+  
without  
T2DM  
n (%) 
Non HCV-
cirrhotic 
controls  
tot. 
Diabetic pts  
among non 
HCV-cirrhotic  
controls  
n (%) 
Non HCV- 
cirrhotic 
controls 
without 
T2DM 
n (%) 
Odds  
ratio 
Relative 
risk 
Allison et al 
(1994)40 
 34 17 (50) 
 
17 (50) 66 6 (9) 60 (91)   
Ozyilkan et al 
(1996)25 
 50 19 (38) 31 (62) 133 16 (12) 117 (88)   
Mangia et al 
(1998)26 
 157 54 (34·4) 103 
(65·6) 
90 26 (28·9) 64 (71·1)   
Guerrero et al 
(1998)41 
 28 8 (28·6) 20 (71·4) 47 5 (10·6) 42 (89·4)   
Caronia et al 
(1999)31 
 1151 272 (23·6) 879 
(76·4) 
181 17 (9·4) 
 
 
164 (90·6) 
 
  
Mason et al 
(1999)33 
 145 48 (33·1) 97 (66·9) 88 18 (20·5) 70 (79·5)   
Bigam et al 
(2000)42 
 110 32 (29) 
 
78 (71) 168 8 (4·8) 160 (95·2)   
Zein et al 
(2000)43 
 73 17 (23·3) 56 (76·7) 131 11 (8·4) 120 (91·6)   
Baid et al 
(2001)44 
 47 8 (17) 39 (83) 111 14 (12·6) 
 
97 (87·4)   
Garrido 
Serrano et al 
(2001)45 
 50 18 (36) 32 (64) 50 9 (18) 41 (82)   
Ryu et al 
(2001)34 
 28 
 
2 (7·1) 26 (92·9) 151 27 (17·9) 124 (82·2)   
Arao et al 
(2003)35 
 234 72 (30·8) 162 
(69·2) 
51 6 (11·8) 45 (88·2)   
Thuluvath et 
al 
(2003)46 
 97 19 (19·6) 78 (80·4) 194 22 (11·3) 
 
172 (88·7)   
Lecube et al 
(2004)36 
 118 47 (39·8) 71 (60·2) 52 19 (36·5) 33 (63·5)   
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Parolin et al 
(2004)47 
 36 13 (36·1) 23 (63·9) 70 18 (25·7) 52 (74·3)   
Rouabhia et 
al 
(2010)39 
 43 29 (67·4) 14 (32·6) 5 1 (20) 4 (80)   
Total  2401 675 1726 1588 223 1365   
        OR  
2·39 
RR  
2·00 
95% 
confidence 
interval 
       2·02–2·84 
p=0·000 
1·74–2·30 
p=0·000 
 
HCV+ = HCV-positive; pts = patients 
	   20	  
Table 2c T2DM prevalence among hepatopathic patients with HCV-related cirrhosis versus HBV-related cirrhosis 
controls 
 
  HCV+ 
tot. 
Diabetic pts 
among HCV + 
n (%) 
HCV+  
without  
T2DM 
n (%) 
 
HBV-
related 
cirrhosis 
controls tot. 
Diabetic pts 
among HBV- 
related 
cirrhosis 
controls n (%) 
HBV- 
related 
cirrhosis 
controls 
without  
T2DM 
n (%) 
Odds  
ratio 
Relative 
risk 
Mangia et al 
(1998)26 
 157 54 (34·4) 103 
(65·6) 
38 12 (31·6) 26 (68·4)   
Caronia et al 
(1999)31 
 1151 272 (23·6) 879 
(76·4) 
181 17 (9·4) 164 (90·6)   
Mason et al 
(1999)33 
 145 48 (33·1) 97 (66·9) 88 18 (20·5) 70 (79·5)   
Bigam et al 
(2000)42 
 110 32 (29) 
 
78 (71) 53 3 (5·7) 50 (94·3)   
Ryu et al 
(2001)34 
 28 
 
2 (7·1) 26 (92·9) 102 14 (13·7) 88 (86·3)   
Arao et al 
(2003)35 
 234 72 (30·8) 162 
(69·2) 
51 6 (11·8) 45 (88·2)   
Rouabhia et 
al 
(2010)39 
 43 29 (67·4) 14 (32·6) 5 1 (20)  4 (80)   
Total  1868 509 1359 518 71 447   
        OR 
2·35 
RR 
1·98 
95% 
confidence 
interval 
       1·75–3·11 
p=0·0000 
1·57–2·52 
p=0·000 
 
HCV+ = HCV-positive; pts = patients 
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Table 3a HCV positive rate among diabetic patients, matched with non diabetic subjects 
 Diabetics 
 
 Non diabetics Odds  
ratio 
Relative 
risk 
 
 tot HCV + 
n (%) 
HCV – 
n (%) 
 Tot HCV+ 
n (%) 
HCV – 
n (%) 
 
  
Simò et al 
(1996)48 
 176 18 (10·2)  158 (89·8)  6172 156 
(2·5)  
6016 (97·5)   
Labropoulou-
Karatza et al 
(1999)32 
 36 30 (83·3) 6 (16·7)  72 34 (47·2) 38 (52·8)   
Rudoni et al 
(1999)49 
 259 
 
8 (3·1)  
 
251 (96·9)  14100 6 (0·1) 14094 (99·9)   
Chen et al 
(2006)50 
 820 56 (6·8) 764 (93·2)  905 23 (2·5) 882 (97·5) 
  
  
Ocak et al 
(2006)51 
 67 14 (20·9) 53 (79·1)  200 20 (10) 180 (90)   
Gulcan et al 
(2008)52  
 617   19 (3·1) 598 (96·9)  314 4 (1·3) 310 (98·7)   
Nwokediuk et al 
(2008)38  
 191 27 (14·1) 164 (85·9)  134 5 (3·7) 129 (96·3)   
Sjöberg et al 
(2008)53 
 375 2 (0·5) 373 (99·5)  331 2 (0·6) 329 (99·4)   
Kaabia et al 
(2009)54 
 1269 17 (1·3) 1252 (98·7)  1315 8 (0·6) 1307 (99·4)   
Jadoon et al 
(2010)55  
 3000 410 (13·7) 2590 (86·3)  10000 496 (5) 9504 (95)   
Chehadeh et al 
(2011)56 
 438 31 (7) 407 (93)  440 4 (1) 436 (99)   
Korkmaz et al 
(2015)57 
 736 24 (3·3) 712 (96·7)  505 9 (1·8) 496 (98·2)   
Total  7984 656 7328  34488 767 33721   
         OR 
3·94 
RR 
2·58 
95% confidence 
interval 
        3·53–4·39 
p=0·0000 
2·43–2·74 
p=0·000 
HCV+ = HCV-positive 
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Table 3b HBV positive rate among diabetic patients, matched with non diabetic subjects 
 
 Diabetics 
 
 Non diabetics Odds  
ratio 
Relative 
risk 
 
 tot HBsAg+ 
n (%) 
HBsAg– 
n (%) 
 tot HBsAg+ 
n (%) 
HBsAg – 
n (%) 
  
Chen et al 
(2006)50 
 820 111 (13·5)  709 (86·5)  905 112 
(12·4)  
793 (87·6)   
Gulcan et al 
(2008)52 
 617 31 (5) 586 (95)  314 12 (3·8) 302 (96·2)   
Korkmaz et al 
(2015)57 
 736 28 (3·8) 708 (96·2)  505 15 (3) 490 (97)  
 
 
Total  2173 170 2003  1724 139 1585   
         OR 
 
0·97 
RR 
 
0·98 
95% confidence 
interval 
        0·76–1·23 
p=ns 
0·87–1·09 
p=ns 
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Figure Legend 
Fig. 1 PRISMA flow chart: data collection and selection of studies 
 
 
 
 
 
544	  individual	  articles	  identified	  
through	  systematic	  review	  
145	  assessed	  for	  inclusion	  criteria	  
71	  	  met	  inclusion	  criteria	  
	  
	  
399	  excluded	  (title	  or	  abstract	  not	  relevant)	  
	  
	  
Multiple	  publications	  using	  the	  same	  data	  were	  deleted	  
(total	  number	  removed	  2)	  
33	  included	  in	  meta-­‐analysis	  
	  
38	  excluded	  
14	  for	  exclusion	  criterion	  1	  
13	  for	  exclusion	  criterion	  2	  
11	  for	  exclusion	  criterion	  3	  
	  
	  
72	  did	  not	  meet	  inclusion	  criteria	  1	  and	  /	  or	  2	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Figure Legend 
Fig. 2a Forest plot related to the studies reported in Table 1a, showing T2DM risk in hepatopathic patients with HCV-
related chronic hepatitis (without cirrhosis) versus non-hepatopathic controls 
Stu dy name Statistics for e ach s tud y Risk ratio and 95% CI
Risk  Lower Upper 
ratio limit l imit Z-Valu e p-Value
O zyilka n, 199 6 13,83 6 4,239 45,167 4,353 0,000
M angia, 19 98 0,60 5 0,266 1,377 -1,197 0,231
Knob le r, 2000 6,00 0 2,328 15,464 3,709 0,000
Antone lli, 2004 2,08 5 1,166 3,729 2,477 0,013
Antone lli, 2005 1,72 8 1,094 2,730 2,344 0,019
2,58 2 1,161 5,746 2,325 0,020
0,01 0,1 1 10 100
Favours A Favours B
Meta Analysis
M eta An al ysis
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Figure Legend 
Fig. 2b Forest plot related to the studies reported in Table 1b, showing T2DM risk among hepatopathic patients with 
HCV-related cirrhosis versus non HCV-cirrhotic controls (with HBV, alcohol, colestatic or cryptogenic disorders, or 
primary biliary cirrhosis or primary sclerosing cholangitis)  
 
 
 
 
Study na me Sta ti stic s for  e ach study Ris k ratio a nd 95 % CI
Risk Low e r Upper  
ratio limit limit Z-Va lue p-Value
Ozyilk an , 1 9 96 3 ,1 8 2 1,5 29 6,62 4 3,0 95 0,002
Grimb ert,  1 99 6 2 ,2 9 5 1,2 44 4,23 5 2,6 59 0,008
Mang ia, 1 998 4 ,6 7 0 0,2 70 8 0,87 8 1,0 59 0,290
Caron ia , 1 9 99 1 ,1 5 4 0,0 49 2 7,16 4 0,0 89 0,929
La b ro po u lo u-Ka ra tza, 19 99 3 ,6 1 0 1,4 58 8,94 2 2,7 74 0,006
Maso n, 19 9 9 1 ,8 9 2 1,0 67 3,35 5 2,1 82 0,029
Kn o bler, 2 000 2 ,6 6 7 1,3 37 5,31 7 2,7 85 0,005
Ryu , 2 00 1 2 ,8 4 2 1,4 48 5,57 7 3,0 36 0,002
Ara o, 20 0 3 1 ,2 6 5 0,7 28 2,19 7 0,8 33 0,405
Le c ub e, 20 04 2 ,6 2 3 1,1 73 5,86 4 2,3 49 0,019
An ton elli, 2 0 05 2 ,5 8 1 0,9 68 6,87 8 1,8 96 0,058
Im a ze ki, 20 08 2 ,1 6 1 1,3 18 3,54 5 3,0 53 0,002
Roua bh ia, 20 10 7 ,7 6 9 3,2 30 1 8,68 5 4,5 79 0,000
2 ,3 9 9 1,9 61 2,93 5 8,4 99 0,000
0,0 1 0,1 1 10 10 0
Favours A Favours B
Meta Analysis
M eta Analysis
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Figure Legend 
Fig. 2c Forest plot related to the studies reported in Table 1c, showing T2DM risk among hepatopathic patients with 
HCV-related chronic hepatitis (without cirrhosis) versus hepatopathic HBV-positive controls 
 
Stu dy name Statistics fo r each study Risk ratio and 95% CI
R isk  Lo wer Up per 
ratio limit limit Z-Valu e p-Value
M angia, 19 98 2,90 3 0,169 49,721 0,735 0,462
C aroni a, 199 9 1,15 4 0,049 27,164 0,089 0,929
M aso n, 1 999 1,89 2 1,067 3,355 2,182 0,029
Knob le r, 2000 2,66 7 1,337 5,317 2,785 0,005
Ryu,  200 1 2,84 2 1,448 5,577 3,036 0,002
Ara o, 2003 1,26 5 0,728 2,197 0,833 0,405
Antone lli, 2005 2,58 1 0,968 6,878 1,896 0,058
Imazeki, 200 8 2,16 1 1,318 3,545 3,053 0,002
Roua bhia, 20 10 7,76 9 3,230 18,685 4,579 0,000
2,25 1 1,769 2,863 6,608 0,000
0,01 0,1 1 10 100
Favours A Favours B
Meta Analysis
M eta An al ysis
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Figure Legend 
Fig. 3a Forest plot related to the studies reported in Table 2a, showing the risk of T2DM in HCV cirrhosis, in 
comparison with “normal” non hepatopathic controls (matched by age and gender) 
Stu dy name Statistics for e ach s tud y Risk ratio and 95% CI
Risk Lower Upper 
ratio limit l imit Z-Valu e p-Value
O zyilka n, 199 6 25,33 3 7,803 82,243 5,380 0,000
M angia, 19 98 3,54 0 2,507 4,997 7,184 0,000
8,70 8 1,275 59,495 2,207 0,027
0,01 0,1 1 10 100
Favours A Favours B
Meta Analysis
M eta An al ysis
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Figure Legend 
Fig. 3b Forest plot related to the studies reported in Table 2b, showing the risk of T2DM in HCV patients with cirrhosis 
in comparison with non HCV-cirrhotic controls (with HBV, alcohol, colestatic or cryptogenic disorders, or primary 
biliary cirrhosis or primary sclerosing cholangitis) 
 
Stud y name Statistics for each study Risk  ratio and 95% CI
Risk Lo wer Upper 
ratio limit l imit Z-Va lue p-Va lue
All ison, 1994 5,50 0 2,389 12,660 4,00 8 0,000
Ozyilkan , 19 96 3,15 9 1,768 5,64 2 3,88 6 0,000
Man gia, 1998 1,19 1 0,806 1,75 8 0,87 8 0,380
Guerrero, 1998 2,68 6 0,974 7,40 8 1,90 8 0,056
Caro nia, 1 999 2,51 6 1,582 4,00 3 3,89 5 0,000
Mason, 19 99 1,61 8 1,009 2,59 6 1,99 7 0,046
Biga m, 20 00 6,10 9 2,925 12,760 4,81 6 0,000
Ze in , 20 00 2,7 3 1,374 5,59 8 2,84 7 0,004
Baid , 2001 1,35 0 0,607 3,00 0 0,73 5 0,462
Garid o Serrano , 2001 2,0 0 0,996 4,01 8 1,94 8 0,051
Ryu, 2001 0,39 9 0,101 1,58 6 -1,305 0,192
Arao , 20 03 2,61 5 1,204 5,68 1 2,42 9 0,015
Thuluva th , 20 03 1,72 7 0,983 3,03 4 1,90 1 0,057
Le cube, 2004 1,09 0 0,715 1,66 1 0,40 1 0,688
Paro lin , 200 4 1,40 4 0,779 2,53 2 1,12 9 0,259
Rouabhia, 2 010 3,37 2 0,577 19,704 1,35 0 0,177
2,02 7 1,541 2,66 5 5,05 9 0,000
0,01 0,1 1 10 100
Favours A Favours B
Meta Analysis
Meta An alysis
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Figure Legend 
Fig. 3c Forest plot related to the studies reported in Table 2c, showing risk of T2DM in HCV cirrhosis in comparison 
with cirrhotic HBV controls 
 
 
	  
Stu dy name Statistics fo r each study Risk ratio and 95% CI
R isk  Lo wer Up per 
ratio limit limit Z-Valu e p-Value
M angia, 19 98 1,08 9 0,650 1,824 0,325 0,745
C aroni a, 199 9 2,51 6 1,582 4,003 3,895 0,000
M aso n, 1 999 1,61 8 1,009 2,596 1,997 0,046
B igam,  2000 5,13 9 1,648 16,024 2,821 0,005
Ryu,  200 1 0,52 0 0,126 2,156 -0,901 0,368
Ara o, 2003 2,61 5 1,204 5,681 2,429 0,015
Roua bhia, 20 10 3,37 2 0,577 19,704 1,350 0,177
1,88 6 1,237 2,874 2,951 0,003
0,01 0,1 1 10 100
Favours A Favours B
Meta Analysis
M eta An al ysis
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Figure Legend 
Fig. 4a Forest plot related to the studies reported in Table 3a, showing risk of HCV infection in diabetic patients versus 
non-diabetic controls 
 
Study nam e Sta ti stic s for  e ach study Risk ratio and 9 5% CI
Risk Low er Uppe r 
ra ti o limit lim it Z-Va lue p-Value
Sim ò , 1 99 6 4 ,0 4 6 2,543 6, 437 5 ,900 0,000
Lab rop ou lou -Kar at za , 1 99 9 1 ,7 6 5 1,328 2, 346 3 ,912 0,000
Ru don i, 1 9 99 72 ,5 8 7 25,367 207, 707 7 ,988 0,000
Ch en, 2 006 2 ,6 8 7 1,669 4, 326 4 ,069 0,000
Oca k, 2 00 6 2 ,0 9 0 1,119 3, 902 2 ,313 0,021
Gu lcan , 200 8 2 ,4 1 7 0,829 7, 045 1 ,617 0,106
Nwo ke diuk, 20 08 3 ,7 8 8 1,497 9, 586 2 ,812 0,005
Sjö berg , 2 00 8 0 ,8 8 3 0,125 6, 231 -0 ,125 0,900
Kaa b ia , 200 9 2 ,2 0 2 0,954 5, 084 1 ,849 0,064
Ja do on , 2 0 10 2 ,7 5 5 2,433 3, 120 15 ,982 0,000
Ch eha de h , 2 01 1 7 ,7 8 5 2,772 21, 870 3 ,894 0,000
Korkma z, 2 015 1 ,8 3 0 0,858 3, 903 1 ,563 0,118
3 ,2 1 7 2,266 4, 567 6 ,537 0,000
0,01 0,1 1 10 1 00
Favours A Favours B
Meta Analysis
Met a An alysis
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Figure Legend 
Fig. 4b Forest plot related to the studies reported in Table 3b, showing the risk of HBV infection in diabetic patients, 
versus non-diabetic controls are reported 
Study  name Statistics for each stu dy R isk ratio and 95% CI
Risk Lower U pper 
ratio l imit limit Z-Value p-Value
Ch en, 200 6 1 ,0 94 0,8 56 1,3 97 0,718 0,473
Gu lcan , 200 8 1 ,3 15 0,6 85 2,5 24 0,822 0,411
Korkmaz, 20 15 1 ,2 81 0,6 91 2,3 73 0,786 0,432
1 ,1 37 0,9 17 1,4 10 1,174 0,240
0,01 0,1 1 10 100
Favours A Favours B
Meta Analysis
Meta An alysis
 
	  
	  
	  
	  
	  
	  
	  
	  
